Clinical Trials Logo

PD-L1 clinical trials

View clinical trials related to PD-L1.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04247217 Completed - Prostate Cancer Clinical Trials

Immune Profiling After HDR in Local Relapsed Prostate Cancer

PRIMUS
Start date: February 19, 2020
Phase:
Study type: Observational

Immunotherapy is currently revolutionizing the field in oncology. However, prostate cancer until now fails to respond to classical IO, like PD-1 and CTLA-4 inhibitors. Radiotherapy (RT) delivered to the primary tumor impacts both tumor cells and surrounding stromal cells. Radiation damage to cancer cells exposes tumor-specific antigens leading to increased visibility to the immune system by improved priming and activation of cytotoxic T cells. RT-induced modulation of the tumor microenvironment may also facilitate the recruitment and infiltration of immune cells by increasing the expression or T-cell attracting chemokines and by increasing T-cell docking molecules on the endothelial cells like VCAM-1. The main-hypothesis is that HDR-brachytherapy will turn an immunologically "cold" (no T-cell infiltrations) prostate cancer into an immunologically "hot" (CD4 and CD8-cell infiltrations) tumor, creating leverage points for different forms of IO.